Total
0
Shares
TBG Diagnostics (ASX:TDL) to sell COVID-19 test kits after Chinese Govt. law lifted
  • TBG Diagnostics (TDL) has announced its subsidiary, TBG Biotechnology, has received CE Mark approval for its COVID-19 Nucleic Acid and Antibody Rapid test kits
  • The CE Mark indicates that the test kits meet the essential health, safety and environmental protection requirements to sell the kits in the European market
  • TBG says the tests take up to 15 minutes to complete and detect COVID-19
  • TBG Diagnostics is still in a trading halt after a sudden spike in its share price, which the company claims was due to its investee company receiving CE mark approval
  • Company shares last traded for 27 cents each on March 17

TBG Diagnostics (TDL) has announced its subsidiary, TBG Biotechnology, has received CE Mark approval for its COVID-19 Nucleic Acid and Antibody Rapid test kits.

The CE Mark approval covers TDL's ExProbeTM SARS-CoV-2 (ExProbe test kit) Testing Kit and its SARS-CoV-2 IgG/IgM Rapid Test Kit (Rapid test kit).

The CE Mark indicates that the test kits meet the essential health, safety and environmental protection requirements to sell the kits in the European market.

Both tests are manufactured by TBG Biotechnology in Taiwan and will be exported from there to the destination country.

TBG says the tests take up to 15 minutes to complete and detect the presence of SARS-CoV-2 specific antibodies, IgM and IgG, in the blood, serum and plasma. This means the test can be used to confirm if a subject has been infected with the COVID-19 virus.

"IgM and IgG antibodies usually generated in the body seven to 10 days after SARS-CoV-2 infection and can last for weeks," the company explained.

This rapid test uses droplets of blood, serum or plasma as test samples.

TBG Diagnostics is still in a trading halt after a sudden spike in its share price, which the company claims was due to its investee company receiving CE mark approval.

Company shares last traded for 27 cents each on March 17.


Subscribe


TDL by the numbers
More From The Market Herald
Living Cell Technologies’ (ASX:LCT) CEO plans for retirement

" Living Cell Technologies’ (ASX:LCT) CEO plans for retirement

Living Cell Technologies’ (LCT) CEO, Dr Ken Taylor, has revealed that he plans to retire from his position this year.
Cyclopharm (ASX:CYC) - Managing Director and CEO, James McBrayer (right) - The Market Herald

" Cyclopharm (ASX:CYC) completes $30M placement

Cyclopharm (CYC) has completed a share placement to investors of approximately 11.5 million new fully paid ordinary shares.
SUDA Pharmaceuticals (ASX:SUD) - Executive Chairman, Paul Hopper - The Market Herald

" SUDA Pharmaceuticals (ASX:SUD) shares drop as MTPS leaves ZolpiMist agreement

SUDA Pharmaceuticals (SUD) shares are down this morning after Mitsubishi Tanabe Pharma Singapore (MTPS) announced it would not proceed with its ZolpiMist agreement.
Cann Global (ASX:CGB) shares on the rise after Thailand’s hemp rules change

" Cann Global (ASX:CGB) shares on the rise after Thailand’s hemp rules change

Cann Global (CGB) shares are on the rise today after Thailand’s regulation for hemp changes.